Following a host of trial flops, Angion halts R&D work, searches for ‘strategic alternatives’

After scrapping a Phase II kidney disease study last month, it appears Angion Biomedica may be out of moves.

The Uniondale, NY-based biotech announced Monday afternoon that it would be looking into “strategic alternatives” — suggesting a potential merger, reverse merger and sale or licensing of its candidates as options it would be exploring. In the meantime, Angion will be shuttering its R&D work.